Haleon PLC

Report Publication Announcement • May 1, 2024

National Storage Mechanism | Additional information

RNS Number : 7006M

Haleon PLC

01 May 2024

Haleon plc: 2024 Q1 Trading Statement

1 May 2024: Haleon plc's Q1 trading update for the year ended 31 December 2024 is available at: http://www.rns-pdf.londonstockexchange.com/rns/7006M_1-2024-4-30.pdf .

The Q1 trading statement will also be available on the Haleon website www.haleon.com/investors , and the statement has been submitted in full unedited text to the Financial Conduct Authority's National Storage Mechanism and will shortly be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism .

Presentation for analysts and shareholders:

A short presentation followed by Q&A will be hosted by Tobias Hestler, Chief Financial Officer and Sonya Ghobrial, Head of Investor Relations at 9:00am BST (10:00am CEST) on 1 May 2024, which can be accessed at www.haleon.com/investors.     

For analysts and shareholders wishing to ask questions on the Q&A call, please use the dial-in details below which will have a Q&A facility:

UK:	+44 800 279 3956
US:	+1 866 291 4166
All other:	+44 (0) 207 107 0613
Passcode:	43700369

An archived webcast of the Q&A call will be available later on the day of the results and can be accessed at www.haleon.com/investors .

Enquiries
Investors		Media
Sonya Ghobrial	+44 7392 784784	Zo ë Bird	+44 7736 746167
Rakesh Patel	+44 7552 484646	Nidaa Lone	+44 7841 400607
Emma White	+44 7823 523562
Email: investor-relations@haleon.com		Email: corporate.media@haleon.com

About Haleon

Haleon (LSE / NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans five major categories - Oral Health, Pain Relief, Respiratory Health, Digestive Health and Other, and Vitamins, Minerals and Supplements (VMS). Its long-standing brands - such as Advil, Sensodyne, Panadol, Voltaren, Theraflu, Otrivin, Polident, parodontax and Centrum - are built on trusted science, innovation and deep human understanding.

For more information, please visit www.haleon.com . 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

TSTSDDFWSELSELL